Literature DB >> 20015893

Molecular analysis of 42 patients with congenital dyserythropoietic anemia type II: new mutations in the SEC23B gene and a search for a genotype-phenotype relationship.

Achille Iolascon1, Roberta Russo, Maria Rosaria Esposito, Roberta Asci, Carmelo Piscopo, Silverio Perrotta, Madeleine Fénéant-Thibault, Loïc Garçon, Jean Delaunay.   

Abstract

BACKGROUND: The most frequent form of congenital dyserythropoietic anemia is the type II form. Recently it was shown that the vast majority of patients with congenital dyserythropoietic anemia type II carry mutations in the SEC23B gene. Here we established the molecular basis of 42 cases of congenital dyserythropoietic anemia type II and attempted to define a genotype-phenotype relationship. DESIGN AND METHODS: SEC23B gene sequencing analysis was performed to assess the diversity and incidence of each mutation in 42 patients with congenital dyserythropoietic anemia type II (25 described exclusively in this work), from the Italian and the French Registries, and the relationship of these mutations with the clinical presentation. To this purpose, we divided the patients into two groups: (i) patients with two missense mutations and (ii) patients with one nonsense and one missense mutation.
RESULTS: We found 22 mutations of uneven frequency, including seven novel mutations. Compound heterozygosity for a missense and a nonsense mutation tended to produce a more severe clinical presentation, a lower reticulocyte count, a higher serum ferritin level, and, in some cases, more pronounced transfusion needs, than homozygosity or compound heterozygosity for two missense mutations. Homozygosity or compound heterozygosity for two nonsense mutations was never found.
CONCLUSIONS: This study allowed us to determine the most frequent mutations in patients with congenital dyserythropoietic anemia type II. Correlations between the mutations and various biological parameters suggested that the association of one missense mutation and one nonsense mutation was significantly more deleterious that the association of two missense mutations. However, there was an overlap between the two categories.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015893      PMCID: PMC2864375          DOI: 10.3324/haematol.2009.014985

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  16 in total

1.  Structure of the Sec23/24-Sar1 pre-budding complex of the COPII vesicle coat.

Authors:  Xiping Bi; Richard A Corpina; Jonathan Goldberg
Journal:  Nature       Date:  2002-09-19       Impact factor: 49.962

Review 2.  Congenital dyserythropoietic anemia type II (CDAII/HEMPAS): where are we now?

Authors:  Jonas Denecke; Thorsten Marquardt
Journal:  Biochim Biophys Acta       Date:  2008-12-25

3.  Congenital dyserythropoietic anaemia, types I and II: aberrant pattern of erythrocyte membrane proteins in CDA II, as revealed by two-dimensional polyacrylamide gel electrophoresis.

Authors:  V Anselstetter; H J Horstmann; H Heimpel
Journal:  Br J Haematol       Date:  1977-02       Impact factor: 6.998

4.  Hereditary erythroblastic multinuclearity associated with a positive acidified-serum test: a type of congenital dyserythropoietic anaemia.

Authors:  J H Crookston; M C Crookston; K L Burnie; W H Francombe; J V Dacie; J A Davis; S M Lewis
Journal:  Br J Haematol       Date:  1969-07       Impact factor: 6.998

5.  Incomplete synthesis of N-glycans in congenital dyserythropoietic anemia type II caused by a defect in the gene encoding alpha-mannosidase II.

Authors:  M N Fukuda; K A Masri; A Dell; L Luzzatto; K W Moremen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 6.  Congenital dyserythropoietic anemia type II: molecular basis and clinical aspects.

Authors:  A Iolascon; G D'Agostaro; S Perrotta; P Izzo; R Tavano; B Miraglia del Giudice
Journal:  Haematologica       Date:  1996 Nov-Dec       Impact factor: 9.941

Review 7.  Congenital dyserythropoietic anemias.

Authors:  S N Wickramasinghe
Journal:  Curr Opin Hematol       Date:  2000-03       Impact factor: 3.284

8.  Primary defect of congenital dyserythropoietic anemia type II. Failure in glycosylation of erythrocyte lactosaminoglycan proteins caused by lowered N-acetylglucosaminyltransferase II.

Authors:  M N Fukuda; A Dell; P Scartezzini
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

9.  The cisternae decorating the red blood cell membrane in congenital dyserythropoietic anemia (type II) originate from the endoplasmic reticulum.

Authors:  N Alloisio; P Texier; L Denoroy; C Berger; E Miraglia del Giudice; S Perrotta; A Iolascon; F Gilsanz; G Berger; J Guichard
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

10.  Congenital dyserythropoietic anemia type II: exclusion of seven candidate genes.

Authors:  Carmela Lanzara; Romina Ficarella; Angela Totaro; Xin Chen; Roberta Roberto; Silverio Perrotta; Carla Lasalandra; Paolo Gasparini; Achille Iolascon; Massimo Carella
Journal:  Blood Cells Mol Dis       Date:  2003 Jan-Feb       Impact factor: 3.039

View more
  24 in total

1.  Molecular basis of congenital dyserythropoietic anemia type II and genotype-phenotype relationship.

Authors:  Mario Cazzola; Rosangela Invernizzi
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

Review 2.  Congenital dyserythropoietic anaemias: new acquisitions.

Authors:  Achille Iolascon; Roberta Russo; Maria Rosaria Esposito; Carmelo Piscopo; Roberta Asci; Luigia De Falco; Francesca Di Noce
Journal:  Blood Transfus       Date:  2010-12-13       Impact factor: 3.443

3.  Identification of biologically relevant enhancers in human erythroid cells.

Authors:  Mack Y Su; Laurie A Steiner; Hannah Bogardus; Tejaswini Mishra; Vincent P Schulz; Ross C Hardison; Patrick G Gallagher
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

4.  Absence of a red blood cell phenotype in mice with hematopoietic deficiency of SEC23B.

Authors:  Rami Khoriaty; Matthew P Vasievich; Morgan Jones; Lesley Everett; Jennifer Chase; Jiayi Tao; David Siemieniak; Bin Zhang; Ivan Maillard; David Ginsburg
Journal:  Mol Cell Biol       Date:  2014-07-28       Impact factor: 4.272

Review 5.  Trafficking mechanisms of extracellular matrix macromolecules: insights from vertebrate development and human diseases.

Authors:  Gokhan Unlu; Daniel S Levic; David B Melville; Ela W Knapik
Journal:  Int J Biochem Cell Biol       Date:  2013-12-09       Impact factor: 5.085

6.  Compound heterozygosity for two novel mutations of the SEC23B gene in congenital dyserythropoietic anemia type II.

Authors:  Shanshan Chen; Ziwen Guo; Yongbin Ye; Shanhong Yang; Guinian Huang
Journal:  Int J Hematol       Date:  2021-04-29       Impact factor: 2.490

7.  SEC23B is required for the maintenance of murine professional secretory tissues.

Authors:  Jiayi Tao; Min Zhu; He Wang; Solomon Afelik; Matthew P Vasievich; Xiao-Wei Chen; Guojing Zhu; Jan Jensen; David Ginsburg; Bin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-28       Impact factor: 11.205

8.  Congenital dyserythropoietic anemia types Ib, II, and III: novel variants in the CDIN1 gene and functional study of a novel variant in the KIF23 gene.

Authors:  Manuel Méndez; María Isabel Moreno-Carralero; Valeria L Peri; Rafael Camacho-Galán; José M Bosch-Benítez; Jorge Huerta-Aragonés; Jorge Sánchez-Calero-Guilarte; María Belén Moreno-Risco; Juan Manuel Alonso-Domínguez; María José Morán-Jiménez
Journal:  Ann Hematol       Date:  2020-11-07       Impact factor: 3.673

9.  Characteristic phenotypes associated with congenital dyserythropoietic anemia (type II) manifest at different stages of erythropoiesis.

Authors:  Timothy J Satchwell; Stephanie Pellegrin; Paola Bianchi; Bethan R Hawley; Alexandra Gampel; Kathryn E Mordue; Annika Budnik; Elisa Fermo; Wilma Barcellini; David J Stephens; Emile van den Akker; Ashley M Toye
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

Review 10.  The COPII pathway and hematologic disease.

Authors:  Rami Khoriaty; Matthew P Vasievich; David Ginsburg
Journal:  Blood       Date:  2012-05-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.